Microsoft vs GeneDx Holdings Corp — how do they compare? Microsoft trades at $500.3 (market cap $3.74T), while GeneDx Holdings Corp trades at $82 (market cap $2.44B). The key difference: Microsoft is far larger — about 1532.8× GeneDx Holdings Corp's market cap, and Microsoft pays a 0.72% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| MSFT | WGS | |
|---|---|---|
Market Cap | $3.74T | $2.44B |
Volume | 36,654,621 | — |
Sector | Technology | Technology |
52-Week High | $542.07 | $167.51 |
52-Week Low | $352.83 | $34.51 |
Enterprise Value | $3.72T | $2.48B |
Dividend Yield | 0.72% | — |
Signals from Pluang's Aura AI — not financial advice
Microsoft (MSFT) trades at $506.06, up 1.21% with strong bullish technical signals from moving averages. The company demonstrates robust fundamentals with $281.72B revenue, 40.31% net margin, and consistent earnings beats. Recent news highlights Microsoft's AI leadership and Azure growth potential, though concerns about capital expenditures persist. The stock trades near pivot point resistance at $507 with strong support at $500.
Outlook remains positive with 80% analyst buy ratings and $552.73 consensus target offering 9% upside. Key opportunities include AI integration and cloud growth, while risks involve competitive pressures and execution on large capital investments. The combination of strong fundamentals and technical momentum supports a constructive view for investors.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →